Table IV.
Univariate analysis for OS predictors.
| Overall survival | P-value | Hazard ratio (95 % CI) |
|---|---|---|
|
| ||
| ECOG (1 vs. 0) | p< 0.001 | HR=4.24 (95% CI 2.1 – 8.57) |
|
| ||
| CEA≥5 ng/mL | p=0.015 | HR=1.02 (95% CI 1.003 – 1.04) |
| Vascular invasion | p=0.027 | HR=2.14 (95% CI 1.07 – 4.25) |
|
| ||
| Lymphatic invasion | p=0.018 | HR=2 (95% CI 1.11 – 3.62) |
|
| ||
| Perineural invasion | p< 0.001 | HR=3.52 (95% CI 1.93 – 6.42) |
|
| ||
| Node capsular effraction | p< 0.001 | HR=3.38 (95% CI 1.67 – 6.86) |
|
| ||
| TNM stage (III vs. II) | p<0.001 | HR=3.62 (95% CI 1.68 – 7.79) |
|
| ||
| Distant recurrence | p<0.001 | HR=18.05 (95% CI 8.83 – 36.91) |
| Local recurrence | p<0.001 | HR=4.28 (95% CI 2.35 – 7.8) |
| Resection margin (R1 vs. R0) | p=0.04 | HR=2.03 (95% CI 1.01 – 4.11) |
ECOG: Eastern Cooperative Oncology Group performance status; CEA: carcinoembryonic antigen